Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 257 clinical trials
A Clinical Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Patients With hATTR-PN

The objective of the study is to characterize adverse events (AEs) occurring within one day of TEGSEDI administration to adult patients with hATTR-PN overall and in individual patients with respect to time course of AE onset, vital sign changes, preventive measures, treatment required, risk factors, and subsequent adverse outcomes.

  • 0 views
  • 23 Dec, 2021
  • 4 locations
Reducing African American's Alzheimer's Risk Through Exercise-Mild Cognitive Impairment (RAATE-MCI) (RAATE-MCI)

The RAATE-MCI proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. RAATE-MCI is a 52-week randomized controlled trial. 144 African American adults aged 60 and …

  • 0 views
  • 11 Mar, 2022
  • 1 location
Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)" (RAATE)

The RAATE proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. There are three main objectives of the protocol: to determine if a physical activity …

mental state examination
mini-mental state examination
Accepts healthy volunteers
  • 0 views
  • 11 Mar, 2022
  • 1 location
A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis

This is an open-label, multicenter, Phase 2 study in subjects with previously treated patients with light chain (AL) amyloidosis in need for therapy. Approximately 35 subjects will

  • 0 views
  • 13 Mar, 2021
  • 5 locations
A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form

abnormal proteins
neutrophil count
immunoglobulin
blood disorder
amyloid deposits
  • 41 views
  • 09 Apr, 2022
  • 62 locations
A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form

abnormal proteins
neutrophil count
immunoglobulin
blood disorder
amyloid deposits
  • 32 views
  • 06 Apr, 2022
  • 64 locations
A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed stage 3B light chain (AL) amyloidosis.

  • 8 views
  • 18 Feb, 2022
  • 5 locations
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

216 weeks of treatment (A45 Trial) and to determine whether treatment with BAN2401 is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography

  • 1 views
  • 20 Jun, 2022
  • 3 locations
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis (AFFIRM-AL)

A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in patients with AL amyloidosis in Mayo Stage IV.

  • 5 views
  • 20 Jun, 2022
  • 75 locations
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

To evaluate the efficacy of eplontersen compared to placebo for 120 weeks in patients with ATTR-CM receiving available standard of care (SoC). For more information, please visit https://www.cardio-ttransform.com.

  • 9 views
  • 18 Apr, 2022
  • 47 locations